Autoimmune disease is controlled by host genes and the environment. Both can increase susceptibility to autoimmunity by affecting the overall reactivity and quality of the cells of the immune system.
Amarna Therapeutics is developing non-immunogenic viral vectors to overcome those limitations and simultaneously unlock an immune tolerance induction approach to treat autoimmune diseases.